Fluocinolone acetonide intravitreal implant - Bausch and Lomb/pSivida

Drug Profile

Fluocinolone acetonide intravitreal implant - Bausch and Lomb/pSivida

Alternative Names: Fluocinolone acetonide Envision TD implant; Retisert

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator pSivida Inc
  • Developer Bausch & Lomb
  • Class Anti-inflammatories; Antipruritics; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules; Vasoconstrictors
  • Mechanism of Action Arachidonic acid inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors; Phospholipase A2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Uveitis
  • Discontinued Age-related macular degeneration; Choroidal neovascularisation; Diabetic macular oedema

Most Recent Events

  • 11 Sep 2017 Fluocinolone acetonide intravitreal implant is licensed to Bausch and Lomb
  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
  • 27 Oct 2007 Bausch and Lomb has been acquired by Warburg Pincus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top